GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mineralys Therapeutics Inc (NAS:MLYS) » Definitions » Volatility

Mineralys Therapeutics (Mineralys Therapeutics) Volatility : 77.21% (As of May. 27, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mineralys Therapeutics Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-05-27), Mineralys Therapeutics's Volatility is 77.21%.


Competitive Comparison of Mineralys Therapeutics's Volatility

For the Biotechnology subindustry, Mineralys Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mineralys Therapeutics's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Mineralys Therapeutics's Volatility falls into.



Mineralys Therapeutics  (NAS:MLYS) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mineralys Therapeutics  (NAS:MLYS) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Mineralys Therapeutics Volatility Related Terms

Thank you for viewing the detailed overview of Mineralys Therapeutics's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Mineralys Therapeutics (Mineralys Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
Executives
Jon Congleton director, officer: Chief Executive Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Glenn Sblendorio director 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
David Malcom Rodman officer: Chief Medical Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Srinivas Akkaraju director, 10 percent owner 565 EVERETT AVENUE, PALO ALTO CA 94301
Hbm Healthcare Investments (cayman) Ltd. 10 percent owner GOVERNORS SQUARE, 23 LIME TREE BAY AVE.,, PO BOX 30852, GRAND CAYMAN E9 KY1-1204
Adam Scott Levy officer: CFO, Chief Bus. Off. and Secy. C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
Catalys Pacific Fund, Lp 10 percent owner 301 9-19 HACHIYAMA, SHIBUYA, TOKYO M0 150-0035
Olivier Litzka director C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Takeshi Takahashi director C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Brian Taylor Slingsby director, 10 percent owner C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Ra Capital Nexus Fund Iii, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Samsara Biocapital, L.p. 10 percent owner 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Alexander Asam director C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361

Mineralys Therapeutics (Mineralys Therapeutics) Headlines

From GuruFocus